VAXCELL-BIO THERAPEUTICS CO., LTD. Funds and ETFs Vaxcell-Bio Therapeutics Co., Ltd.
Equities
A323990
KR7323990002
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,220 KRW | -4.12% |
|
-16.20% | -23.30% |
| 2023 | Vaxcell-Bio Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Vaxcell-Bio Therapeutics Co., Ltd.(KOSDAQ:A323990) added to S&P Global BMI Index | CI |
ETFs positioned on Vaxcell-Bio Therapeutics Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - |
Vaxcell-Bio Therapeutics is a Korea-based company mainly engaged in the research and development of anti-angiogenic immunotherapy drugs. The Company's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The Company sells its products in domestic and overseas markets.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.30% | 286M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A323990 Stock
- Funds and ETFs Vaxcell-Bio Therapeutics Co., Ltd.
